

Using Psilocybin to Target Relapse in Opioid Addiction

Imran Shah*

Department of Molecular Medicine, University of Lahore, Pakistan

Introduction

Opioid addiction continues to be one of the most severe public health crises globally, with millions of individuals affected and countless lives lost due to overdose. Despite the availability of treatments like methadone, buprenorphine, and behavioral therapies, relapse rates remain stubbornly high, with approximately 40-60% of individuals returning to opioid use within a year after treatment. Recent research suggests that psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, may offer a novel and effective approach to reducing relapse rates and aiding long-term recovery in opioid addiction. This article explores the mechanisms, benefits, challenges, and future potential of psilocybin-assisted therapy for targeting relapse in opioid addiction [1].

Understanding opioid addiction and relapse

Opioid addiction is characterized by compulsive drug-seeking behavior and a high risk of relapse even after prolonged periods of abstinence. This is due to several factors:

Neurobiological changes: Chronic opioid use alters brain circuits involved in reward, stress, and self-control.

Psychological factors: Anxiety, depression, and unresolved trauma often co-occur with opioid addiction.

Environmental triggers: Exposure to stress or cues associated with drug use can strongly predict relapse.

Current treatments focus on managing withdrawal symptoms, reducing cravings, and promoting behavioral changes. However, these interventions often fail to address the underlying psychological and spiritual dimensions of addiction, which can leave individuals vulnerable to relapse [2].

Psilocybin: mechanisms of action

Psilocybin is a prodrug that, when ingested, is converted into psilocin, an active compound that primarily affects serotonin 2A (5-HT_{2A}) receptors in the brain. This receptor activation leads to altered states of consciousness, including profound changes in perception, emotion, and cognition. Key mechanisms relevant to addiction treatment include:

Neuroplasticity: Psilocybin promotes neural plasticity, enabling the brain to rewire itself and form new, healthier patterns of thinking and behaviour [3].

Emotional processing: It facilitates access to deep-seated emotions and memories, helping individuals confront and process past traumas.

Disruption of maladaptive patterns: The compound interrupts habitual patterns of thought, including cravings and negative self-perceptions, which are common in addiction.

Spiritual insights: Many individuals report a sense of connection, purpose, and transcendence during psilocybin experiences, which can foster motivation for recovery.

Clinical evidence for psilocybin in addiction treatment

Though research on psilocybin for opioid addiction is still in its infancy, studies on other substance use disorders provide compelling evidence:

Alcohol use disorder: A randomized clinical trial showed significant reductions in drinking days and cravings among participants who underwent psilocybin-assisted therapy compared to placebo groups [4].

Tobacco addiction: In a pilot study, 80% of participants achieved abstinence from smoking after psilocybin-assisted therapy, a rate far exceeding traditional cessation programs.

Opioid use disorder: Emerging data from preclinical studies and anecdotal reports suggest that psilocybin may reduce cravings and improve emotional resilience, but robust clinical trials are still needed.

The success of these studies underscores psilocybin's potential to address the psychological and behavioral dimensions of addiction that are often overlooked in conventional treatments [5].

Psilocybin-assisted therapy: a holistic approach

Psilocybin is most effective when administered as part of a comprehensive therapeutic framework. This typically includes the following components:

Preparation: Participants undergo several preparatory sessions to build trust with therapists, set intentions, and address concerns about the experience.

Dosing session: A psilocybin session typically lasts 6-8 hours, during which participants are encouraged to explore their inner experiences in a safe and supportive environment [6].

Integration: Post-session therapy focuses on processing insights gained during the experience and incorporating them into daily life.

This approach ensures that psilocybin's transformative effects are harnessed effectively and sustainably.

Benefits of psilocybin for relapse prevention in opioid addiction

Craving reduction: Psilocybin has been shown to diminish cravings by altering reward pathways and providing individuals with a renewed sense of purpose.

***Corresponding author:** Imran Shah, Department of Molecular Medicine, University of Lahore, Pakistan, E-mail: imran.shah@unilhr.edu.pk

Received: 01-Nov-2024; Manuscript No: jpar-24-153041; **Editor assigned:** 04-Nov-2024, PreQC No: jpar-24-153041(PQ); **Reviewed:** 18-Nov-2024; QC No: jpar-24-153041; **Revised:** 22-Nov-2024, Manuscript No: jpar-24-153041(R); **Published:** 29-Nov-2024, DOI: 10.4172/2167-0846.1000682

Citation: Imran S (2024) Using Psilocybin to Target Relapse in Opioid Addiction. J Pain Relief 13: 682.

Copyright: © 2024 Imran S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Emotional resilience: By helping individuals process trauma and reduce anxiety, psilocybin enhances emotional stability, which is crucial for resisting relapse [7].

Improved mental health: Many opioid users suffer from co-occurring mental health disorders. Psilocybin's antidepressant and anxiolytic effects can address these issues.

Long-lasting effects: Unlike daily medications, a single psilocybin session can yield sustained benefits, reducing the burden of ongoing treatment.

Challenges and barriers to implementation

While the potential of psilocybin-assisted therapy is promising, several challenges remain:

Legal and regulatory hurdles: Psilocybin is classified as a Schedule I substance in many countries, making research and clinical application difficult [8].

Stigma: Psychedelics carry historical stigma due to their association with counterculture movements, which may deter acceptance among healthcare providers and patients.

Variability in response: Not all individuals respond positively to psilocybin, and some may experience adverse effects such as anxiety or confusion during sessions.

Need for trained therapists: The success of psilocybin therapy depends heavily on skilled facilitators, necessitating extensive training and certification programs.

Future directions and research priorities

To fully realize the potential of psilocybin for opioid addiction, further research and development are needed in the following areas:

Large-scale clinical trials: Rigorous studies are essential to establish the safety, efficacy, and optimal protocols for psilocybin-assisted therapy in opioid addiction [9].

Personalized approaches: Research should explore how individual factors, such as genetic predispositions and psychological profiles, influence treatment outcomes.

Combination therapies: Investigating how psilocybin can be integrated with existing pharmacological and behavioral therapies may yield synergistic effects.

Policy advocacy: Efforts to reclassify psilocybin and educate policymakers on its benefits are crucial for expanding access to this treatment.

Ethical and societal considerations

The use of psychedelics in medicine raises important ethical questions. Ensuring equitable access, informed consent, and culturally sensitive care will be critical as psilocybin transitions from research

settings to broader clinical use. Additionally, public education campaigns can help dispel myths and promote informed discourse about psychedelic therapies [10].

Conclusion

Psilocybin represents a groundbreaking approach to addressing the complex and multifaceted challenges of opioid addiction relapse. By targeting the psychological and emotional roots of addiction, psilocybin-assisted therapy has the potential to complement existing treatments and significantly improve recovery outcomes. While challenges remain, the growing body of evidence and ongoing clinical trials signal a promising future for psilocybin as a tool in combating the opioid crisis. As research progresses and societal attitudes evolve, psilocybin may emerge as a key component in the fight against addiction, offering hope to millions worldwide.

Acknowledgement

None

Conflict of Interest

None

References

1. Solomonow-Avnon D, Haim A, Levin D, Elboim-Gabyzon M, Rozen N, et al. (2016) Reduction of hip joint reaction force via medio-lateral foot center of pressure manipulation in bilateral hip osteoarthritis patients. *J Orthop Res* 34: 1762-1771.
2. Miles C, Greene A (2020) The effect of treatment with a non-invasive foot worn biomechanical device on subjective and objective measures in patients with knee osteoarthritis- a retrospective analysis on a UK population. *BMC Musculoskelet Disord* 21: 386.
3. Greene A, Miles C (2022) Surgery avoidance rates among total knee replacement candidates following a non-invasive biomechanical intervention: A retrospective cohort study. *Journal of Orthopaedic Experience and Innovation*.
4. Reichenbach S, Felson DT, Hincapié CA, Heldner S, Bütikofer L, et al. (2020) Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis: The BIOTOK Randomized Clinical Trial. *JAMA* 323: 1802-1812.
5. NICE MTG (2023) AposHealth for knee osteoarthritis.
6. Haim A, Rozen N, Wolf A (2010) The influence of sagittal center of pressure offset on gait kinematics and kinetics. *J Biomech* 43: 969-977.
7. Haim A, Wolf A, Rubin G, Genis Y, Khoury M, et al. (2011) Effect of center of pressure modulation on knee adduction moment in medial compartment knee osteoarthritis. *J Orthop Res* 29: 1668-1674.
8. Solomonow-Avnon D, Herman A, Wolf A (2019) Mechanism of reducing knee adduction moment by shortening of the knee lever arm via medio-lateral manipulation of foot center of pressure: A pilot study. *J Biomech* 83: 143-149.
9. Debbi EM, Wolf A, Haim A (2012) Detecting and quantifying global instability during a dynamic task using kinetic and kinematic gait parameters. *J Biomech* 45: 1366-1371.
10. Hmamouchi I, Allali F, Tahiri L, Khazzani H, Mansouri LE, et al. (2012) Clinically important improvement in the WOMAC and predictor factors for response to non-specific non-steroidal anti-inflammatory drugs in osteoarthritic patients: a prospective study. *BMC Res Notes* 5: 58.